Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

5 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Design of a potent and selective dual JAK1/TYK2 inhibitor.
Mammoliti O, Menet C, Cottereaux C, Blanc J, De Blieck A, Coti G, Geney R, Oste L, Ostyn K, Palisse A, Quinton E, Schmitt B, Borgonovi M, Parent I, Jagerschmidt C, De Vos S, Vayssiere B, López-Ramos M, Shoji K, Brys R, Amantini D, Galien R, Joannesse C. Mammoliti O, et al. Among authors: coti g. Bioorg Med Chem. 2024 Nov 15;114:117932. doi: 10.1016/j.bmc.2024.117932. Epub 2024 Sep 30. Bioorg Med Chem. 2024. PMID: 39447537 Free article.
Discovery of GLPG3667, a Selective ATP Competitive Tyrosine Kinase 2 Inhibitor for the Treatment of Autoimmune Diseases.
Mammoliti O, Martina S, Claes P, Coti G, Blanque R, Jagerschmidt C, Shoji K, Borgonovi M, De Vos S, Marsais F, Oste L, Quinton E, López-Ramos M, Amantini D, Brys R, Jimenez JM, Galien R, van der Plas S. Mammoliti O, et al. Among authors: coti g. J Med Chem. 2024 Jun 13;67(11):8545-8568. doi: 10.1021/acs.jmedchem.4c00769. Epub 2024 May 28. J Med Chem. 2024. PMID: 38805213 Free PMC article. Clinical Trial.
Discovery of GLPG2737, a Potent Type 2 Corrector of CFTR for the Treatment of Cystic Fibrosis in Combination with a Potentiator and a Type 1 Co-corrector.
Pizzonero M, Akkari R, Bock X, Gosmini R, De Lemos E, Duthion B, Newsome G, Mai TT, Roques V, Jary H, Lefrancois JM, Cherel L, Quenehen V, Babel M, Merayo N, Bienvenu N, Mammoliti O, Coti G, Palisse A, Cowart M, Shrestha A, Greszler S, Van Der Plas S, Jansen K, Claes P, Jans M, Gees M, Borgonovi M, De Wilde G, Conrath K. Pizzonero M, et al. Among authors: coti g. J Med Chem. 2024 Apr 11;67(7):5216-5232. doi: 10.1021/acs.jmedchem.3c01790. Epub 2024 Mar 25. J Med Chem. 2024. PMID: 38527911 Free PMC article.
Prognostic value of copeptin and mid-regional proadrenomedullin in COVID-19-hospitalized patients.
Indirli R, Bandera A, Valenti L, Ceriotti F, Di Modugno A, Tettamanti M, Gualtierotti R, Peyvandi F, Montano N, Blasi F, Costantino G, Resi V, Orsi E, Arosio M, Mantovani G, Ferrante E; COVID-19 Network Working Group. Indirli R, et al. Eur J Clin Invest. 2022 May;52(5):e13753. doi: 10.1111/eci.13753. Epub 2022 Feb 7. Eur J Clin Invest. 2022. PMID: 35128648 Free PMC article.
Synthesis and biological evaluation of antifungal derivatives of enfumafungin as orally bioavailable inhibitors of β-1,3-glucan synthase.
Heasley BH, Pacofsky GJ, Mamai A, Liu H, Nelson K, Coti G, Peel MR, Balkovec JM, Greenlee ML, Liberator P, Meng D, Parker DL, Wilkening RR, Apgar JM, Racine F, Hsu MJ, Giacobbe RA, Kahn JN. Heasley BH, et al. Among authors: coti g. Bioorg Med Chem Lett. 2012 Nov 15;22(22):6811-6. doi: 10.1016/j.bmcl.2012.05.031. Epub 2012 May 17. Bioorg Med Chem Lett. 2012. PMID: 22672801